Medpace posts $707M quarter, beating estimates as revenue climbs 17%
What's the deal? Medpace HoldingsDealroom has a profile for this one. Try Dealroom → reported $707.33 million in revenue for the quarter ended in July, up 17.2% year on year and ahead of the $689.51 million analysts expected. Earnings came in at $4.25 per share, beating the $3.98 consensus.
Why it matters: MedpaceDealroom has a profile for this one. Try Dealroom → runs clinical trials for drug and device developers, making its results a read on demand for outsourced pharmaceutical research. The company earned $3.10 per share in the same quarter last year.
By the numbers: Medpace posted a return on equity of 110.15% and a net margin of 17.67%. It carries a market capitalisation of $16.55 billion and a price-to-earnings ratio of 34.76.
What's the endgame? The company set FY 2026 guidance at $17.25 to $17.95 in earnings per share. Analysts forecast $17.54 per share for the current fiscal year.
Zoom in: Shares opened at $593.02, near the middle of a 52-week range that runs from $373.00 to $677.90. The stock trades above both its 50-day average of $571.91 and its 200-day average of $497.71.
Yes, but: Insiders have been selling. Director Fred B. Davenport, Jr. sold 7,283 shares on August 19 at an average $606.15, cutting his stake 65.73%, while director Brian T. Carley sold 5,000 shares the same day at $608.63. Across the quarter, insiders sold 134,471 shares worth $82.15 million.
The signal: Institutional interest continues to build alongside the sell-side caution. HSBC HoldingsDealroom has a profile for this one. Try Dealroom → opened a new position of 977 shares worth about $518,000 in the second quarter, joining a wave of smaller funds. Hedge funds and other institutional investors now own 77.98% of Medpace stock, even as analysts hold ratings around "neutral" with price targets clustered near $620.
Read more: americanbankingnews.com
Image credit: w_lemay
